Uploaded October 2026 | Updated November 2026, 3 days ago
What is heart failure with LVEF ≥40%—and why is it becoming a bigger share of heart failure hospitalizations? In this interview, cardiologist Dr. Scott Solomon (Harvard Medical School; Brigham and Women’s Hospital) explains how left ventricular ejection fraction (LVEF) is used to describe heart function—and what it means when LVEF is 40% or higher.
In this video, you’ll hear evidence-based context on:
- What heart failure is and why it is a leading cause of hospitalization in people over 65
- What “left ventricular ejection fraction” measures (the proportion of blood pumped from the left ventricle with each contraction)
- How heart failure is commonly described across LVEF less than 40% and LVEF ≥40%
- Why comorbidities may be more common when LVEF is ≥40%
- Why treatment approaches and evidence can differ across LVEF groups
- Observational estimates of economic burden, including cost and expenditure figures referenced in the video
Bayer Global shares science-driven conversations to support understanding of cardiovascular conditions and their potential impact on patients and health systems. This video is for informational purposes only and is not a substitute for medical advice. Healthcare professionals should use their independent medical judgment.
What is heart failure with LVEF ≥40%—and why is it becoming a bigger share of heart failure hospitalizations? In this interview, cardiologist Dr. Scott Solomon (Harvard Medical School; Brigham and Women’s Hospital) explains how left ventricular ejection fraction (LVEF) is used to describe heart function—and what it means when LVEF is 40% or higher.
In this video, you’ll hear evidence-based context on:
- What heart failure is and why it is a leading cause of hospitalization in people over 65
- What “left ventricular ejection fraction” measures (the proportion of blood pumped from the left ventricle with each contraction)
- How heart failure is commonly described across LVEF less than 40% and LVEF ≥40%
- Why comorbidities may be more common when LVEF is ≥40%
- Why treatment approaches and evidence can differ across LVEF groups
- Observational estimates of economic burden, including cost and expenditure figures referenced in the video
Bayer Global shares science-driven conversations to support understanding of cardiovascular conditions and their potential impact on patients and health systems. This video is for informational purposes only and is not a substitute for medical advice. Healthcare professionals should use their independent medical judgment.










